Skip to main content

FCPM III Services B.V.

13F filer · CIK 0002013410
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$750MU.S. long equity reported on 13F
Positions111 new · 0 closed
Net flow last quarter-$12.9MBuys minus sells
Top 10 positions weight99.9%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202611 positions
NAMSNewAmsterdam Pharma Co N.V.$288M38.34%7.22%-7.7%Q4 2023
MPLTMapLight Therapeutics, Inc.$116M15.41%7.10%Not reportedQ4 2025
DYNDyne Therapeutics, Inc.$85.5M11.39%2.32%-17.1%Q4 2023
VORVor Biopharma Inc.$75.8M10.10%7.56%Not reportedQ3 2025
DMRADamora Therapeutics, Inc.$63.5M8.46%3.95%Not reportedQ1 2026
REPLReplimune Group, Inc.$31.1M4.14%3.34%Not reportedQ4 2023
CBIOCrescent Biopharma, Inc.$30.2M4.02%6.05%Not reportedQ4 2025
AURAAura Biosciences, Inc.$28.8M3.84%3.92%NewQ2 2026
ENGNenGene Therapeutics Inc.$16.7M2.22%14.38%Not reportedQ4 2023
BCYCBicycle Therapeutics PLC$14.7M1.96%4.97%Not reportedQ2 2024
ENGNWenGene Therapeutics Inc.$834K0.11%Not reportedNot reportedQ4 2023
Q1 2026Reported May 15, 202610 positions
NAMSNewAmsterdam Pharma Co N.V.$294M40.77%7.89%Not reportedQ4 2023
DYNDyne Therapeutics, Inc.$84.2M11.66%2.81%-15.0%Q4 2023
VORVor Biopharma Inc.$73.5M10.17%7.60%+13.8%Q3 2025
ENGNenGene Therapeutics Inc.$65.6M9.08%14.38%Not reportedQ4 2023
MPLTMapLight Therapeutics, Inc.$65.6M9.08%7.14%Not reportedQ4 2025
DMRADamora Therapeutics, Inc.$63.2M8.75%4.05%NewQ1 2026
CBIOCrescent Biopharma, Inc.$30.8M4.27%6.09%Not reportedQ4 2025
REPLReplimune Group, Inc.$21.5M2.97%3.40%Not reportedQ4 2023
BCYCBicycle Therapeutics PLC$16.1M2.23%4.98%Not reportedQ2 2024
ENGNWenGene Therapeutics Inc.$7.28M1.01%Not reportedNot reportedQ4 2023
Q4 2025Reported Feb 17, 202610 positions
NAMSNewAmsterdam Pharma Co N.V.$323M42.30%8.04%-0.2%Q4 2023
DYNDyne Therapeutics, Inc.$107M14.01%3.31%Not reportedQ4 2023
ENGNenGene Therapeutics Inc.$87M11.40%14.38%Not reportedQ4 2023
RAPTRAPT Therapeutics, Inc.$62.1M8.14%6.62%+432.6%Q2 2025
MPLTMapLight Therapeutics, Inc.$56.7M7.43%7.33%NewQ4 2025
VORVor Biopharma Inc.$47.3M6.20%9.34%+852.8%Q3 2025
REPLReplimune Group, Inc.$27.3M3.58%3.53%-32.5%Q4 2023
BCYCBicycle Therapeutics PLC$24.6M3.22%5.00%+0.5%Q2 2024
CBIOCrescent Biopharma, Inc.$19.9M2.61%6.09%NewQ4 2025
ENGNWenGene Therapeutics Inc.$8.52M1.12%Not reportedNot reportedQ4 2023
Q3 2025Reported Nov 14, 20259 positions
NAMSNewAmsterdam Pharma Co N.V.$262M52.36%8.14%-13.4%Q4 2023
DYNDyne Therapeutics, Inc.$69.1M13.81%3.83%Not reportedQ4 2023
ENGNenGene Therapeutics Inc.$65.8M13.15%18.82%Not reportedQ4 2023
ATXSAstria Therapeutics, Inc.$29.9M5.98%7.28%Not reportedQ4 2024
BCYCBicycle Therapeutics PLC$26.7M5.34%4.98%Not reportedQ2 2024
VORVor Biopharma Inc.$18.5M3.70%4.21%NewQ3 2025
REPLReplimune Group, Inc.$17.4M3.48%5.30%+6.4%Q4 2023
RAPTRAPT Therapeutics, Inc.$8.88M1.77%2.08%-21.8%Q2 2025
ENGNWenGene Therapeutics Inc.$2.07M0.41%Not reportedNot reportedQ4 2023
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.